Health-related quality of life in patients with haemophilia and inhibitors on prophylaxis with anti-inhibitor complex concentrate: results from the Pro-FEIBA study.
about
Estimates of utility weights in hemophilia: implications for cost-utility analysis of clotting factor prophylaxisThe evolution of comprehensive haemophilia care in the United States: perspectives from the frontline.Global Post-Authorization Safety Surveillance Study: real-world data on prophylaxis and on-demand treatment using FEIBA (an activated prothrombin complex concentrate).Treatment and Prevention of Bleeds in Haemophilia Patients with Inhibitors to Factor VIII/IXThe social burden and quality of life of patients with haemophilia in Italy.Current and evolving features in the clinical management of haemophiliaIs There Evidence for Neurocognitive Dysfunctions in Patients with Postnatal HIV Infection? A Review on the Cohort of Hemophilia PatientsPrinciples of treatment and update of recommendations for the management of haemophilia and congenital bleeding disorders in ItalyA Cohort Pilot Study on HIV-Associated Neuropsychological Impairments in Hemophilia Patients.Predictors of quality of life among adolescents and young adults with a bleeding disorderPrevention of bleeding in hemophilia patients with high-titer inhibitors.Health-related quality of life assessment in haemophilia patients on prophylaxis therapy: a systematic review of results from prospective clinical trials.The Role of Frontal-Subcortical Circuitry in Neuropsychological Deficit of Attention: Hypothesis and Results in Two Coagulation Disorders.The impact of a haemophilia education intervention on the knowledge and health related quality of life of parents of Indian children with haemophilia.Cost analysis of prophylaxis with activated prothrombin complex concentrate vs. on-demand therapy with activated factor VII in severe haemophilia A patients with inhibitors, in Spain.Impact of severe haemophilia A on patients' health status: results from the guardian(™) 1 clinical trial of turoctocog alfa (NovoEight(®) ).Perceived challenges and attitudes to regimen and product selection from Italian haemophilia treaters: the 2013 AICE survey.Bypassing agent prophylaxis in people with hemophilia A or B with inhibitors.Patient and parent preferences for characteristics of prophylactic treatment in hemophilia.Prophylaxis with anti-inhibitor coagulant complex improves health-related quality of life in haemophilia patients with inhibitors: results from FEIBA NF Prophylaxis Study.A Comparison of Efficacy Between Recombinant Activated Factor VII (Aryoseven) and Novoseven in Patients With Hereditary FVIII Deficiency With Inhibitor.Assessing options for treating haemophilia with inhibitors.Modern Treatments of Haemophilia: Review of Cost-Effectiveness Analyses and Future Directions.Non-factor replacement therapy for haemophilia: a current update.
P2860
Q26865814-3B4C8676-37B3-44AD-83D4-71B45C080627Q30249256-106B3780-E0E8-44E4-8D70-FF5DC65EAD0BQ31041664-F1765D32-B515-4585-A6BB-65E91C6B6927Q33608230-F5741FC2-6EF2-4B73-9F36-43D9919B3816Q33708947-80C9E22F-FC12-47BB-BC93-49C171D4C335Q33708976-A2022ED4-E957-48BB-A657-A9F153C6760BQ33794596-0F5909EC-81B9-422D-94C3-8239EBE9D8B6Q34416394-9DA09F94-2B01-4641-A803-C2CB60F61ED9Q35672791-85039940-0571-4CB8-A94D-43D7527D145AQ37740965-7449C058-5D27-48E9-BB08-3C7C3347475DQ38456352-5C63106B-2DAE-4FCE-83E5-C24CAF242D75Q38590269-02D799DB-5A2C-4AD0-B633-F06EA9ED48A8Q38852268-5978A874-9D3A-4DDB-99E9-3CF45E9194B8Q40576526-664B0FE8-DBFD-4527-9C64-9FC92D7DD754Q41099388-40A83AA6-AE00-4032-A703-4C82B7F9BF9AQ41441975-5F11877C-22E0-43AB-837E-47E946B1AAD3Q42236600-93FF08CB-A309-4A1A-858D-504B6450E6ABQ42692841-0250174F-9E10-458B-9BC9-ECA6CD7400D8Q43148985-FB9921C2-9CA9-44CC-9C11-C75402587D14Q45862969-2BDC739F-B98B-4715-A7F5-CB676C01374EQ45869626-3F091574-CDFF-478F-B6E8-78F8D91DD08EQ45874793-14425A29-6CE7-4138-8F03-CE2F35F8FEB6Q45874959-9ED70C6D-23AA-41A0-93A1-9812612F6F2DQ52362938-A39B3BE1-1E71-44EB-BE55-F9F18EAE2018
P2860
Health-related quality of life in patients with haemophilia and inhibitors on prophylaxis with anti-inhibitor complex concentrate: results from the Pro-FEIBA study.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年学术文章
@wuu
2013年学术文章
@zh-cn
2013年学术文章
@zh-hans
2013年学术文章
@zh-my
2013年学术文章
@zh-sg
2013年學術文章
@yue
2013年學術文章
@zh
2013年學術文章
@zh-hant
name
Health-related quality of life ...... ults from the Pro-FEIBA study.
@en
Health-related quality of life ...... ults from the Pro-FEIBA study.
@nl
type
label
Health-related quality of life ...... ults from the Pro-FEIBA study.
@en
Health-related quality of life ...... ults from the Pro-FEIBA study.
@nl
prefLabel
Health-related quality of life ...... ults from the Pro-FEIBA study.
@en
Health-related quality of life ...... ults from the Pro-FEIBA study.
@nl
P2093
P2860
P50
P921
P356
P1433
P1476
Health-related quality of life ...... sults from the Pro-FEIBA study
@en
P2093
A Gringeri
B Zülfikar
C Leissinger
E Berntorp
P2860
P304
P356
10.1111/HAE.12178
P577
2013-06-04T00:00:00Z